UPSC MainsECONOMICS-PAPER-II201615 Marks150 Words
हिंदी में पढ़ें
Q11.

Examine the implications of Trade Related Intellectual Property Rights (TRIPS) on Indian Economy.

How to Approach

This question requires a nuanced understanding of the TRIPS agreement and its multifaceted impact on the Indian economy. The answer should begin by defining TRIPS and its core principles. Then, it should analyze the implications across various sectors – pharmaceuticals, agriculture, and manufacturing – highlighting both positive and negative consequences. Focus on the challenges faced by India in complying with TRIPS, the benefits derived, and the overall impact on innovation, access to essential medicines, and economic growth. A structured approach, using sector-specific examples, will be beneficial.

Model Answer

0 min read

Introduction

The Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement is an international agreement administered by the World Trade Organization (WTO) that sets minimum standards for the protection of intellectual property rights (IPR). Enforced since 1995, TRIPS aimed to reduce distortions and impediments to international trade resulting from differences in national IPR laws. For India, a developing nation with a significant generic drug industry and a large agricultural sector, the implementation of TRIPS presented both opportunities and challenges. Initially, the transition period allowed until 2005 for product patents in pharmaceuticals, but its implications continue to shape India’s economic landscape, impacting innovation, affordability, and competitiveness.

Impact on the Pharmaceutical Sector

The pharmaceutical sector experienced the most significant impact. Before TRIPS, India’s generic drug industry flourished due to process patents, allowing reverse engineering and affordable medication. The introduction of product patents in 2005, as mandated by TRIPS, led to:

  • Increased R&D investment: Indian pharmaceutical companies began investing more in research and development to innovate and create new drugs.
  • Higher drug prices: The cost of patented drugs increased, impacting access to essential medicines, particularly for the poor.
  • Evergreening: Companies attempted to extend patent protection through minor modifications to existing drugs, raising concerns about affordability.

The use of compulsory licensing, as permitted under TRIPS Article 54, has been a crucial mechanism for India to balance patent protection with public health needs. For example, Natco Pharma’s compulsory license for Sorafenib (a liver cancer drug) in 2012 demonstrated India’s commitment to affordable healthcare.

Impact on the Agricultural Sector

TRIPS’s impact on agriculture revolves around the protection of plant varieties through Plant Breeders’ Rights (PBR). This has several implications:

  • Increased seed prices: PBRs allow seed companies to control the market for protected varieties, potentially increasing seed prices for farmers.
  • Reduced farmer’s rights: Restrictions on farmers’ ability to save, exchange, and reuse seeds from protected varieties.
  • Impact on biodiversity: Concerns that PBRs may incentivize the development of a limited number of high-yielding varieties, potentially reducing agricultural biodiversity.

India’s Protection of Plant Varieties and Farmers’ Rights (PPVF) Act, 2001, attempts to balance the interests of plant breeders and farmers, but its implementation remains a challenge.

Impact on the Manufacturing Sector

The manufacturing sector benefited from TRIPS in some ways, particularly in industries reliant on branding and technological innovation:

  • Increased foreign investment: Stronger IPR protection attracted foreign investment in sectors like automobiles, electronics, and software.
  • Enhanced technology transfer: Companies were more willing to transfer technology to India knowing their intellectual property would be protected.
  • Promotion of innovation: TRIPS incentivized domestic companies to invest in R&D and develop their own technologies.

However, challenges remain in enforcing IPR laws effectively, particularly regarding counterfeiting and piracy.

Overall Economic Implications

TRIPS has had a mixed impact on the Indian economy. While it has stimulated innovation and attracted foreign investment, it has also raised costs for consumers and created challenges for certain sectors. According to a 2005 UNCTAD study, the implementation of TRIPS could lead to a net transfer of resources from developing to developed countries. India’s ability to leverage flexibilities within the TRIPS agreement, such as compulsory licensing and the use of the Doha Declaration on TRIPS and Public Health, has been crucial in mitigating some of the negative consequences.

Sector Positive Impacts Negative Impacts
Pharmaceuticals Increased R&D, improved quality standards Higher drug prices, reduced access to medicines
Agriculture Incentive for seed innovation Increased seed costs, reduced farmer’s rights
Manufacturing Increased FDI, technology transfer Challenges in IPR enforcement

Conclusion

The TRIPS agreement has fundamentally reshaped India’s economic landscape, presenting a complex interplay of benefits and drawbacks. While it has fostered innovation and attracted investment, concerns regarding affordability, access to essential medicines, and farmer’s rights persist. India’s strategic use of TRIPS flexibilities and continued investment in R&D are crucial for maximizing the benefits of IPR protection while safeguarding public health and promoting equitable economic growth. Moving forward, strengthening IPR enforcement and fostering a balanced approach to innovation will be key to harnessing the full potential of the TRIPS agreement.

Answer Length

This is a comprehensive model answer for learning purposes and may exceed the word limit. In the exam, always adhere to the prescribed word count.

Additional Resources

Key Definitions

Compulsory Licensing
A provision within TRIPS allowing governments to authorize the use of a patented invention without the patent holder’s consent, typically in cases of public health emergencies or national interest.
Evergreening
The practice of obtaining new patents for minor modifications to existing drugs to extend patent protection beyond the original patent’s expiry date.

Key Statistics

India is the largest provider of generic drugs globally, supplying over 80% of the antiretroviral drugs used in developing countries (UNAIDS, 2021 - knowledge cutoff).

Source: UNAIDS

India’s pharmaceutical industry is estimated to be worth $50 billion in 2023 and is expected to reach $120 billion by 2030 (IBEF, 2023 - knowledge cutoff).

Source: IBEF (India Brand Equity Foundation)

Examples

Novartis Case

Novartis’s attempt to patent Glivec, a life-saving cancer drug, in India was rejected by the Indian Supreme Court in 2013, upholding the principle that patents should be granted for genuine inventions and not merely for new forms of known substances.

Frequently Asked Questions

How does TRIPS affect the cost of medicines in India?

TRIPS, by introducing product patents, generally increases the cost of patented medicines. However, India’s use of compulsory licensing and the robust generic drug industry help to mitigate this impact by providing affordable alternatives.

Topics Covered

EconomyInternational RelationsTradeIntellectual PropertyWTO